

References for Product 23055

1. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem*, 280, 5892.
2. Mathis CA, Wang Y, Klunk WE. (2004) Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. *Curr Pharm Des*, 10, 1469.
3. Lee VM. (2002) Amyloid binding ligands as Alzheimer's disease therapies. *Neurobiol Aging*, 23, 1039.
4. Ishii K, Klunk WE, Arawaka S, Debnath ML, Furiya Y, Sahara N, Shoji S, Tamaoka A, Pettegrew JW, Mori H. (2002) Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. *Neurosci Lett*, 333, 5.
5. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. *J Neuropathol Exp Neurol*, 61, 797.
6. Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. (2001) Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. *Neurobiol Dis*, 8, 1017.
7. Lee VW, Shah NP. (2001) In search of the ideal radiotracer for soft-tissue amyloid scanning. *Amyloid*, 8, 220.
8. Dezutter NA, Landman WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, Zekarias B, Gruys E, Verbruggen AM. (2001) Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. *Amyloid*, 8, 202.
9. Dezutter NA, Sciort RM, de Groot TJ, Bormans GM, Verbruggen AM. (2001) In vitro affinity of 99Tcm-labelled N2S2 conjugates of chrysamine G for amyloid deposits of systemic amyloidosis. *Nucl Med Commun*, 22, 553.
10. Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE. (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. *Proc Natl Acad Sci U S A*, 97, 6739.
11. Dezutter NA, Dom RJ, de Groot TJ, Bormans GM, Verbruggen AM. (1999) 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. *Eur J Nucl Med*, 26, 1392.
12. Klunk WE, Debnath ML, Koros AM, Pettegrew JW. (1998) Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. *Life Sci*, 63, 1807.
13. Klunk WE, Debnath ML, Pettegrew JW. (1995) Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. *Neurobiol Aging*, 16, 541.
14. Klunk WE, Debnath ML, Pettegrew JW. (1994) Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. *Neurobiol Aging*, 15, 691.